• Eitan Amir, Laszlo Mandoky, Fiona Blackhall, Nick Thatcher, Walter Klepetko, AnkersmitHendrik JanHJ, Mir Ali Reza Hoda, Gyula Ostoros, Magdolna Dank, and Balazs Dome.
• Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, UK.
• Expert Opin Investig Drugs. 2009 Nov 1; 18 (11): 1667-86.

BackgroundDespite improvements in surgery and chemo(radio)therapy which have allowed for modest advances in the treatment of patients with non-small-cell lung cancer (NSCLC), survival remains poor and further improvements are needed. Attention over recent years has focused, therefore, on targeted therapies, with notable success in the development of antivascular drugs.ObjectiveTo summarize the current knowledge on antivascular therapy in patients with NSCLC.MethodReview of randomized controlled trials exploring treatment of NSCLC patients with antivascular drugs.Results/ConclusionBevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), when added to cytotoxic chemotherapy, was the first treatment to prolong the overall survival of patients with advanced NSCLC beyond 12 months, a significant breakthrough in the management of advanced NSCLC. Small-molecule tyrosine kinase inhibitors and alternative antivascular strategies such as VEGF-trap and vascular disrupting agents are also being investigated and have shown promise in clinical trials. This review summarizes the most recent and important findings in antivascular agents in NSCLC.

23 keywords...

hide…